Helen of Troy Q4 and 2007
This article was originally published in The Rose Sheet
Executive Summary
Revenue grew 7% to $143.8 mil. during the fourth quarter (ended Feb. 28) on sales of personal-care appliances in Europe and the U.S., firm reports May 11. The quarter marked the completion of the product development process for the new Bed Head by TIGI line, expected to launch during Q2, CEO Gerald J. Rubin says. The company announced last year that it would unveil products under the Bed Head and Toni & Guy brands (1"The Rose Sheet" Dec. 18, 2006, In Brief). 2007 sales grew 7.7% to $634.9 mil. on increases in all areas of business, firm says. In 2008, Helen of Troy will focus on domestic placement of Bed Head and on international sales of Toni & Guy, with sales expected to top $660 mil. The recent acquisition of Belson Products also will provide "additional growth opportunity" for the professional appliance division, Rubin adds (2"The Rose Sheet" May 14, 2007, In Brief)...
You may also be interested in...
Helen of Troy expands portfolio
Company will introduce personal care products under the Toni & Guy and Bed Head by Tigi brand names in North and South America early next year, under a licensing agreement with Stone America announced Dec. 11. A marketing campaign will roll out to the U.S. before expanding to other markets next year; product shipments are slated to begin in 2007. "We are excited about the prospects for these brands and hope that products sold under these trademarks will become one of the most significant personal care categories for Helen of Troy over the long term," President and CEO Gerald Rubin stated. The firm's portfolio includes Revlon, Sea Breeze and Vidal Sassoon...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.